ribosomal protein L22 pseudogene 24Genealiases: []
Q-omics provides the consensus-scored RPL22P24 profile across patient tissues and cancer cell-line models. RPL22P24 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL22P24 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, RPL22P24 RNA expression shows 18,977 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, BLCA, and KIRP as cancer lineages where RPL22P24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL22P24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL22P24 survival associations across molecular data types. RPL22P24 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL22P24 RNA expression–survival associations across cancer types. High RPL22P24 expression shows unfavorable associations in STAD, KICH and LGG, but favorable associations in KIRC, COAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL22P24 RNA expression.
This table summarizes RPL22P24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL22P24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL22P24 shows lower tumor expression in THCA and higher tumor expression in BLCA, HNSC, BRCA, KIRC and LIHC. The BLCA box plot shows higher RPL22P24 RNA expression in tumor versus normal tissue (log2 FC = +0.853, t-test p < 0.001).
This table shows molecular features associated with RPL22P24 in patient tissues and cancer cell lines. In patient samples, RPL22P24 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
